跳至主要内容
临床试验/NCT02677090
NCT02677090已完成不适用

Fiber Tolerability In Children Aged 3-7 Year

Société des Produits Nestlé (SPN)1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2016年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
36
试验地点
1
主要终点
Assessment of the digestive tolerability of the Investigational Product (abdominal pain) using analog visual scale

研究概览

简要总结

Determination of the digestive tolerability of the PROMITOR® in children from 3 to 7 years old.

详细描述

The aim of the trial is to determine, using a dose escalation design, the digestive tolerability of the PROMITOR®given at the doses of 6, then 9 and finally 12 g (corresponding to 4, 6, and 8 g of fibers respectively) twice a day with the meals of the morning and of the evening versus control (maltodextrin, no fiber) over one week of intake in children from 3 to 7 years old.

As it is an exploratory study there is no categorization between primary and secondary objectives.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
3 Years 至 7 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Healthy children
  • Aged between 3 and 7 years old
  • Acceptance of the taste of the product
  • Having breakfast on daily basis
  • Consent and/or assent received according to regulation
  • Informed consent of both parents/guardians (in respect with the French regulation)
  • Parents/guardians affiliated to a health insurance (in respect with the French regulation)

排除标准

  • Specific food regimen
  • Intolerability or food allergy
  • Antibiotic or any medication impacting the gut transit during the 2 weeks before the study
  • Chronic gastrointestinal disease
  • Gastroenteritis in the 2 weeks preceding the study
  • Constipation or diarrhea based on ROMEIII criteria (in average: more than 3 stools per day or less than 3 stools per week)
  • Children and parents expected not to understand and perform the trial correctly (i.e.: troubles in learning and/or speaking)
  • Child in a situation which, in the opinion of the principal investigator, could interfere with the optimal participation to the study or constitute a particular risk of non-compliance
  • Having participated in another clinical trial for 1 month, or currently participating in a clinical trial
  • Under legal protection or deprived from his rights following administrative or judicial decision (in respect with the French regulation)

研究组 & 干预措施

Placebo

Placebo Comparator

Placebo

干预措施: Placebo (including Maltodextrin) (Drug)

Dose 1 - Promitor®

Active Comparator

Investigational product Dose 1

干预措施: Dose 1 - Promitor® (Drug)

Dose 2 - Promitor®

Active Comparator

Investigational product Dose 2

干预措施: Dose 2 - Promitor® (Drug)

Dose 3 - Promitor®

Active Comparator

Investigational product Dose 3

干预措施: Dose 3 - Promitor® (Drug)

结局指标

主要结局

Assessment of the digestive tolerability of the Investigational Product (abdominal pain) using analog visual scale

时间窗: 7 days of intake

Using analog visual scale

Assessment of the digestive tolerability of the Investigational Product (bloating) using analog visual scale

时间窗: 7 days of intake

Using analog visual scale

Assessment of the digestive tolerability of the Investigational Product (rumbling) using analog visual scale

时间窗: 7 days of intake

Using analog visual scale

Assessment of the digestive tolerability of the Investigational Product (stools consistency & frequency) using analog visual scale

时间窗: 7 days of intake

Using analog visual scale

Assessment of the digestive tolerability of the Investigational Product (flatulence) using analog visual scale

时间窗: 7 days of intake

Using analog visual scale

次要结局

未报告次要终点

研究者

发起方
Société des Produits Nestlé (SPN)
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验